Literature DB >> 11483849

Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child.

J M Kramer1, P LaRussa, W C Tsai, P Carney, S M Leber, S Gahagan, S Steinberg, R A Blackwood.   

Abstract

The Food and Drug Administration licensed a live-virus varicella vaccine (Varivax; Merck & Co Inc, West Point, PA) in March 1995. Prelicensure adverse events were minimal; however, since licensure and increased vaccine use, rare previously undetected risks have arisen. Presented here is the clinical course of a previously undiagnosed, human immunodeficiency virus-infected boy who developed dissemination of the vaccine strain of varicella zoster after immunization. chickenpox, human immunodeficiency virus, pneumonia, encephalopathy, varicella vaccine, adverse events, dissemination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483849     DOI: 10.1542/peds.108.2.e39

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Vaccination to prevent varicella and shingles.

Authors:  S J Katona
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

2.  A Toddler With Rash, Encephalopathy, and Hemolytic Anemia.

Authors:  Christiana Smith; Cullen Dutmer; D Scott Schmid; Megan K Dishop; William J Bellini; Erwin W Gelfand; Edwin J Asturias
Journal:  J Pediatric Infect Dis Soc       Date:  2015-05-28       Impact factor: 3.164

Review 3.  Vaccination in HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2014-07-16       Impact factor: 5.078

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 5.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Updated Recommendations for the Use of Varicella and MMR Vaccines In HIV-Infected Individuals: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Ben Tan; Shainoor Ismail
Journal:  Can Commun Dis Rep       Date:  2010-09-16

7.  Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.

Authors:  Benjamin M Stermole; Greg A Grandits; Mollie P Roediger; Brychan M Clark; Anuradha Ganesan; Amy C Weintrob; Nancy F Crum-Cianflone; Tomas M Ferguson; Grace E Macalino; Michael L Landrum
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

8.  Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.

Authors:  Mark L Quinlivan; Anne A Gershon; Mahmoud M Al Bassam; Sharon P Steinberg; Philip LaRussa; Richard A Nichols; Judith Breuer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

Review 9.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.